Simpson-Golabi-Behmel syndrome
MONDO:0010731Simpson-Golabi-Behmel syndrome is a rare X-linked multiple congenital anomalies syndrome, characterized by pre- and postnatal overgrowth, distinctive craniofacial features, variable congenital malformations, organomegaly and an increased tumor risk.
Also known as: DGSX, Golabi-Rosen syndrome, SDYS, SGB syndrome, SGBS, Sara Angers syndrome, Simpson-Golabi-Behmel syndrome, X-linked dysplasia gigantism syndrome
11 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for advanced cancers? first human trial launches
Disease control Recruiting nowThis early-stage study is testing a new drug called BGB-B2033, alone or with other drugs, in people with advanced liver, stomach, or lung cancers. The goal is to see if it is safe and how well it works. About 392 participants will take part.
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New antibody takes aim at Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests a new drug called AZD9793 in people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells find and attack cancer cells. The main goals are to check if the drug is safe and if it can shrink tumors. About 304 a…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests a new treatment for adults with advanced liver cancer that cannot be removed by surgery or has spread. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor, designed to target two proteins found on liver cancer cells. Participa…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug AST-201 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new drug called AST-201 in about 70 adults with advanced solid tumors that have a protein called GPC3. The main goal is to check the drug's safety and find the right dose. Researchers will also measure how the drug moves through the body and look fo…
Phase: PHASE1 • Sponsor: Aptamer Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental antibody targets childhood cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a drug called codrituzumab in children and young adults (ages 1 to 21) whose solid tumors have come back or not responded to treatment and carry a specific protein called GPC3. The main goal is to find a safe dose and see how the body handles the drug…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug MT-303 takes on advanced liver cancer in first human trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called MT-303, alone or with two standard cancer drugs, in people with advanced liver cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see early signs of effectiveness. About 70 …
Phase: PHASE1 • Sponsor: Myeloid Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New imaging agent could sharpen liver cancer detection
Diagnosis Recruiting nowThis study tests a new radioactive tracer called 68Ga-GPC3 that targets a protein found on liver cancer cells. About 40 adults with suspected or confirmed hepatocellular carcinoma will receive both this new tracer and a standard tracer (18F-FDG) for PET/CT scans. Researchers will…
Phase: NA • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New PET scan technique could sharpen cancer detection in the gut
Diagnosis Recruiting nowThis study is testing a new type of PET scan that uses special probes to highlight digestive system cancers, such as stomach, liver, colon, and pancreatic cancers. Researchers will enroll 400 adults to see how well this imaging method finds tumors and tracks their response to tre…
Phase: NA • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
Blood protein may reveal who benefits from liver cancer immunotherapy
Knowledge-focused Recruiting nowThis study is for adults with advanced liver cancer who are starting a common immunotherapy combination (Atezolizumab and Bevacizumab). Researchers want to see if levels of a protein called Glypican-3 in the blood can help predict how well the treatment works. About 240 participa…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC